Current Status and Future Direction of Albumin-Bilirubin in Hepatocellular Carcinoma: A Bibliometric Analysis
Oncology · 2024 · 102 (1) · 43-52
DOI: 10.1159/000533585 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncology, online erschienen am 14.08.2023. Verfasst von Youao Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: The First School of Clinical Medicine, Southern Medical University, Guangzhou, China, 1372330529@qq.com. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Introduction
Hepatocellular carcinoma (HCC) is a common malignant tumor, so we need a convenient and objective way to diagnose and treat HCC. We discuss the current situation, progress, hotspots, and existing problems of Albumin-Bilirubin (ALBI) in HCC, which can provide new ideas for the prevention, diagnosis, and treatment of HCC.
Methods
We adopt Excel 2019 software and visual analysis tools based on Web of Science database search. This manuscript uses VOSviewer, Co-Occurrence13.3 (COOC13.3) software to conduct overall trend analysis, synonym merging, frequency of countries, journals, institutions, funds, dissimilarity matrices, co-occurrence matrices, bimodal matrices, coupling matrices, cluster analysis of topic evolution time zone graphs.
Results
A total of 610 papers were included, and the number of papers output showed an overall upward trend. ALBI has been valued by the industry in HCC and plays an important role in diagnosing and treating HCC, even better than the classic Child-Pugh (C-P) grade. At the same time, hot spots in the treatment of HCC and other applications of ALBI were discovered.
Conclusion
ALBI score is a convenient and objective liver function evaluation index, which plays an important role in the prediction of patient survival rate and prognosis. Promoting the ALBI score in HCC can help doctors judge the patient’s condition and improve the diagnosis and precise treatment effect.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First School of Clinical Medicine, Southern Medical University, Guangzhou, China, 1372330529@qq.com.
- Department of Urology, The People's Hospital of Longhua, The Affiliated Hospital of Southern Medical University, Shenzhen, China, 1372330529@qq.com.
- The First School of Clinical Medicine, Southern Medical University, Guangzhou, China.
- School of Laboratory Medicine and Biotechnology, Southern Medical University, Guangzhou, China.
- Department of Urology, The People's Hospital of Longhua, The Affiliated Hospital of Southern Medical University, Shenzhen, China.
Zitieren
APA
Zhang, Y., Yang, H., Zhou, Q., Chen, K., Wang, J., & Liang, H. (2024). Current Status and Future Direction of Albumin-Bilirubin in Hepatocellular Carcinoma: A Bibliometric Analysis. Oncology, 102(1), 43-52. https://doi.org/10.1159/000533585
Vancouver
Zhang Y, Yang H, Zhou Q, Chen K, Wang J, Liang H. Current Status and Future Direction of Albumin-Bilirubin in Hepatocellular Carcinoma: A Bibliometric Analysis. Oncology. 2024;102(1):43-52. doi:10.1159/000533585
BibTeX
@article{Zhang2024,
author = {Zhang, Youao and Yang, Huiling and Zhou, Qi and Chen, Ke and Wang, Jieyan and Liang, Hui},
title = {Current Status and Future Direction of Albumin-Bilirubin in Hepatocellular Carcinoma: A Bibliometric Analysis},
journal = {Oncology},
year = {2024},
volume = {102},
number = {1},
pages = {43--52},
doi = {10.1159/000533585}
}
EUVIMED